Capricor Therapeutics (CAPR) announced the appointment of Michael Binks, M.D., as Chief Medical Officer, effective immediately. Dr. Binks brings 25 years of experience leading global clinical development and translational research across the pharmaceutical and biotechnology sectors.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CAPR:
- Capricor Therapeutics, Inc. (CAPR) Q1 Earnings Cheat Sheet
- Capricor FDA panel meeting ‘not unexpected,’ says JonesResearch
- Capricor share weakness unwarranted, says H.C. Wainwright
- Capricor completes mid-cycle review with FDA for BLA for deramiocel
- Vaccine, gene therapy makers fall after Peter Marks resignation